2012 related articles for article (PubMed ID: 26387758)
1. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
[TBL] [Abstract][Full Text] [Related]
2. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
[TBL] [Abstract][Full Text] [Related]
3. Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
Dragan I; Wright D; Fiolna M; Leipold G; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Feb; 49(2):209-212. PubMed ID: 27671743
[TBL] [Abstract][Full Text] [Related]
4. Screening for pre-eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation.
Sokratous N; Wright A; Syngelaki A; Kakouri E; Laich A; Nicolaides KH
Ultrasound Obstet Gynecol; 2024 Jan; 63(1):88-97. PubMed ID: 37724582
[TBL] [Abstract][Full Text] [Related]
5. Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks' gestation.
Litwinska M; Syngelaki A; Wright A; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2018 Sep; 52(3):365-372. PubMed ID: 29943498
[TBL] [Abstract][Full Text] [Related]
6. Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.
Tan MY; Wright D; Koutoulas L; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Feb; 49(2):201-208. PubMed ID: 27671370
[TBL] [Abstract][Full Text] [Related]
7. Addition of N-terminal pro-B natriuretic peptide to soluble fms-like tyrosine kinase-1/placental growth factor ratio > 38 improves prediction of pre-eclampsia requiring delivery within 1 week: a longitudinal cohort study.
Sabriá E; Lequerica-Fernández P; Lafuente-Ganuza P; Eguia-Ángeles E; Escudero AI; Martínez-Morillo E; Barceló C; Álvarez FV
Ultrasound Obstet Gynecol; 2018 Jun; 51(6):758-767. PubMed ID: 29498431
[TBL] [Abstract][Full Text] [Related]
8. Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation.
Wright D; Dragan I; Syngelaki A; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Feb; 49(2):194-200. PubMed ID: 27671544
[TBL] [Abstract][Full Text] [Related]
9. [Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia].
Gao J; Shen J; Jiang Y; Zhou X; Qi H; Liu X; Liu J; Yang J; Bian X
Zhonghua Fu Chan Ke Za Zhi; 2014 Jan; 49(1):22-5. PubMed ID: 24694913
[TBL] [Abstract][Full Text] [Related]
10. Screening for pre-eclampsia at 35-37 weeks' gestation.
Panaitescu A; Ciobanu A; Syngelaki A; Wright A; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2018 Oct; 52(4):501-506. PubMed ID: 29896778
[TBL] [Abstract][Full Text] [Related]
11. Maternal serum soluble fms-like tyrosine kinase-1 at 22 and 32 weeks in the prediction of pre-eclampsia.
Wright D; Krajewska K; Bogdanova A; Wright A; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Jun; 47(6):755-61. PubMed ID: 26726123
[TBL] [Abstract][Full Text] [Related]
12. sFlt-1/PlGF for prediction of early-onset pre-eclampsia: STEPS (Study of Early Pre-eclampsia in Spain).
Perales A; Delgado JL; de la Calle M; García-Hernández JA; Escudero AI; Campillos JM; Sarabia MD; Laíz B; Duque M; Navarro M; Calmarza P; Hund M; Álvarez FV;
Ultrasound Obstet Gynecol; 2017 Sep; 50(3):373-382. PubMed ID: 27883242
[TBL] [Abstract][Full Text] [Related]
13. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
[TBL] [Abstract][Full Text] [Related]
14. Levels of serum-circulating angiogenic factors within 1 week prior to delivery are closely related to conditions of pregnant women with pre-eclampsia, gestational hypertension, and/or fetal growth restriction.
Nanjo S; Minami S; Mizoguchi M; Yamamoto M; Yahata T; Toujima S; Shiro M; Kobayashi A; Muragaki Y; Ino K
J Obstet Gynaecol Res; 2017 Dec; 43(12):1805-1814. PubMed ID: 28929598
[TBL] [Abstract][Full Text] [Related]
15. Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tsiakkas A; Mendez O; Wright A; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Apr; 47(4):478-83. PubMed ID: 26582564
[TBL] [Abstract][Full Text] [Related]
16. Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.
Andrietti S; Silva M; Wright A; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Jul; 48(1):72-9. PubMed ID: 26566592
[TBL] [Abstract][Full Text] [Related]
17. Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks' gestation.
Litwinska M; Litwinska E; Astudillo A; Syngelaki A; Wright A; Nicolaides KH
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):360-368. PubMed ID: 33794058
[TBL] [Abstract][Full Text] [Related]
18. Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 35-37 weeks' gestation.
Panaitescu AM; Wright D; Militello A; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Sep; 50(3):383-387. PubMed ID: 28133834
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal change of sFlt-1/PlGF ratio in singleton pregnancy with early-onset fetal growth restriction.
Herraiz I; Quezada MS; Rodriguez-Calvo J; Gómez-Montes E; Villalaín C; Galindo A
Ultrasound Obstet Gynecol; 2018 Nov; 52(5):631-638. PubMed ID: 28876491
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
